CSF taurine level is influenced by plasma cholesterol and the CYP2D6 phenotype

Nordin, Conny; Dahl, Marja-Liisa; Eklundh, Thomas; Eriksson, Mats; Sjöberg, Stefan

doi:10.1016/S0924-977X(03)00033-6

« Previous Next »European Neuropsychopharmacology
Volume 13, Issue 5 , Pages 333-335, October 2003

CSF taurine level is influenced by plasma cholesterol and the CYP2D6 phenotype

Conny Nordin
- Division of Psychiatry, Department of Neuroscience and Locomotion, University Hospital, SE-581 85 Linköping, Sweden
- Corresponding author. Tel.: +46-13-223-864; fax: +46-13-223-392.
Marja-Liisa Dahl
- Department of Medical Sciences, Clinical Pharmacology, Uppsala University Hospital, SE-751 85, Uppsala, Sweden
Thomas Eklundh
- Department of Clinical Neuroscience, Psychiatric Section at the Karolinska Institute, St Görans Hospital, SE-112 81 Stockholm, Sweden
Mats Eriksson
- Department of Medicine, Centre for Metabolism and Endocrinology at the Karolinska Institute, Huddinge Hospital, SE-141 86 Huddinge, Sweden
Stefan Sjöberg
- Department of Medicine, Centre for Metabolism and Endocrinology at the Karolinska Institute, Huddinge Hospital, SE-141 86 Huddinge, Sweden

Received 29 October 2002; received in revised form 6 February 2003; accepted 6 February 2003.

Abstract

Eight healthy male volunteers, lumbar-punctured before and during simvastatin treatment, were phenotyped for CYP2D6 analysis of the debrisoquine metabolic ratio (the ratio between the urinary recovery of debrisoquine and its 4-hydroxy metabolite) after a single oral dose of debrisoquine. The mean cerebrospinal fluid concentrations of cholesterol and taurine did not differ before and during treatment. During (but not before) treatment taurine in the CSF correlated with the debrisoquine metabolic ratio (r=−0.93; P=0.0007) Our results might indicate an influence of CYP2D6 on the level of taurine in the CSF that was secondary to the change in plasma cholesterol.

Keywords: Taurine, Cholesterol, CSF, CYP2D6